All patients in high-risk primary or secondary prevention should be treated with lipid-lowering drugs, regardless of their cholesterol levels. Groundbreaking results from the Heart Protection Study

pp 581-583

Authors

  • Carlos D. Tajer

DOI:

https://doi.org/10.7775/rac.v69i6.3014

Downloads

Published

2026-03-02

Issue

Section

CARDIOLOGICAL NEWS

Most read articles by the same author(s)

1 2 3 4 5 6 > >>